EUCTR2016-001567-37-NL进行中(未招募)1 期
Efficacy of single dose intranasal dexmedetomidine for conscious sedation in dental practice in dentophobic uncooperative patients with intellectual disability. - KUKIDEX-2
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Intellectual Disability of DSM-V classes Mild to Profound
- •2.Documented failure to tolerate the indicated dental treatment with non-pharmacological support.
- •3.Indication for dental treatment under general anesthesia because of 1 and 2.
- •4.Completed and cleared through the pre-anesthetic screening as per the standard protocol of the UMCGs department of anesthesiology
- •5.Adult, men and women, 18-55 years of age, inclusive.
- •6.Body Mass Index (BMI) = 17.5 and = 35 kg/m2, inclusive, and a total body weight >50 kg, at screening and check-in.
- •7.American Society of Anesthesiologists (ASA) Physical Status 1-3
- •8.Able to understand the study procedures as described in the patient information sheet, willing and able to comply with the protocol, and to provide written informed consent OR in the case of legal incapability: a guardian understanding the study procedures as described in the patient information sheet, provides written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Contraindications for the use of dexmedetomidine
- •2.Known intolerance to dexmedetomidine
- •3.History or presence of significant cardiovascular disease (ASA >3), or significant cardiovascular disease risk factors, significant coronary artery disease, or any known genetic pre disposition to cardiac arrhythmia (including long QT syndrome.)
- •4.History or presence of significant (ASA >3) pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, disease.
- •5.History of any illness or medication use that, in the opinion of the PI, might confound the results of the study or pose an additional risk to the subject by their participation in the study.
- •6.Difficulty in airway management anticipated by the attending anesthesiologist .
- •7.Surgery within the past 90 days prior to dosing judged by the PI to be clinically relevant.
- •8.History of febrile illness within 5 days prior to dosing.
- •9.History or presence of alcoholism or drug abuse within the past 2 years.
- •10.Hypersensitivity or idiosyncratic reaction to components of dexmedetomidine, , or to compounds related to the study medications.
- •11.Patients refusal or, in case of legal incapability:
- •12.Guardians refusal
研究者
相似试验
已完成
2 期
Efficacy of single dose intranasal dexmedetomidine for conscious sedation in dental practice in dentophobic uncooperative patients with intellectual disability.Verstandelijke beperkingdentophobiafear for dentist10002861NL-OMON43058niversitair Medisch Centrum Groningen30
尚未招募
不适用
Efficacy of single dose intranasal dexmedetomidine for conscious sedation in dental practice in dentophobic uncooperative patients with intellectual disabilityDentophobiaIntelelctual disabilityNL-OMON28972MCG30
尚未招募
3 期
Role of dexmedetomidine spary through nasal route on patients comfort and sedation during fiber optic intubation in unstable cervical spine fracture.CTRI/2019/03/018027BANGUR INSTITUE OF NEUROSCIENCES
已完成
4 期
Comparison of Dexmedetomidine and Midazolam as Intanasal Premedication in ChildreCTRI/2018/03/012807Principle Investigator104
已完成
不适用
A COMPARATIVE STUDY OF INTRANASAL DEXMEDETOMIDINE AND INTRANASAL MIDAZOLAM FOR PREMEDICATION IN CHILDREN POSTED FOR TONSILLECTOMYCTRI/2021/07/034831Sri Manakula Vinayagar Medical College and Hospital100
